跳至主要内容
临床试验/NCT00810563
NCT00810563Unknown不适用

Assessment of Postoperatory Pain After Laparoscopic Tubal Ligation by Electrocoagulation With Bupivacaine or Placebo

Hospital de Clinicas de Porto Alegre1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2008年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
46
试验地点
1
主要终点
Pain

研究概览

简要总结

The use of bupivacaine , an anesthesic, in laparoscopic portals is recommended in some surgeries. In the ase of tubal ligation by electrocoagulation, where pain is reduced, there is no evidence of this benefit. The objective of this study is to verify the degree of pain after laparoscopic tubal ligation surgery in patient who received bupivacaine 0.5% in the portal, or placebo

详细描述

In order to conduct this study, the internal and external validation were considered.

The author will use different gynecological teams, with different expertise to perform the laparoscopic tubal ligation, but using the same surgical and anesthesic technique. Second year residents, during their rotation, and medical staff will perform the surgery.

Anesthesic technique:

Intravenous remifentanil 0.1-0.5 micrograms/kg/min Intravenous Propofol target controlled or sevoflurane Intermittent ventilation using O2 40 - 100%, with or without compressed air. Before incision: 5mL of bupivacaine 0.5% or saline solution 0.9% from the aponeurosis until the skin In the end of the procedure: intravenous 4mg of dexamethasone + 40mg of tenoxican

Post-operation prescription:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • All patients schedule for laparoscopic tubal ligation

排除标准

  • Not willing to consent
  • Use of analgesic within 12 hours prior the surgery
  • Known allergy or contraindications to bupivacaine, dipyrone, porphine, or sodium diclofenac

研究组 & 干预措施

1

Placebo Comparator

Saline solution 0.9% 5mL in each portal

干预措施: Saline solution (laparoscopic tubal ligation) (Drug)

2

Active Comparator

Bupivacaine 0.5% 5mL in each portal

干预措施: Bupivacaine (Drug)

结局指标

主要结局

Pain

时间窗: at 15, 30 and 120 minutes and 14 hours after surgery

次要结局

  • Use of medication for pain(at 15, 30 and 120 minutes after surgery and 14 hours later)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验